Institutional pharmacy operator dispensing medications to residents of senior living and long-term care facilities.
Institutional pharmacy operator dispensing medications to residents of senior living and long-term care facilities.
Dispenses medications resident by resident and is paid per prescription, mainly by Medicare Part D drug plans, Medicaid and private payers rather than the facility itself. It operates through a set of local pharmacies, each close to the facilities it serves, and has grown by buying small institutional pharmacies.
Moat: narrow (switching costs, scale, regulatory licence). Facility contracts and integrated dispensing systems are disruptive and costly for operators to switch.
Headquarters: Atlanta, Georgia, US · Employees: 3,600
Size Guardian Pharmacy Services (GRDN) is a United States Consumer Staples company (Drugstore Chains) with a market value of $3.09B, the 1517th largest of 3,085 United States companies the cockpit tracks. Shares closed at $48.84 on 18 Nov 2026.
Performance Over six months the shares gained 29.8%, against +10.3% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 11 in its peer set.
Growth Revenue grew 4.8% over the last twelve months (peer median +6.4%); the operating margin is 6.3% (peer median 4.8%).
Valuation It trades at 33.3× forward earnings against a peer median of 16.6× (most expensive of 10).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 28.5 points above its cost of capital (6.6% WACC).
Short interest Short interest is 3.5% of the free float (30 Oct 2026).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.46B | $1.45B | $1.23B | $1.05B | $909M |
| Revenue growth | — | +18% | +17% | +15% | — |
| Gross profit | $327M | $282M | $235M | $200M | $178M |
| EBITDA | $116M | $111M | -$43.1M | $59.2M | $68.6M |
| Net income | $74.8M | $49.2M | -$110M | $23.9M | $35.4M |
| Free cash flow | $96.2M | $80.7M | $41.6M | $56.3M | $31.8M |
| Capital expenditure | $17.9M | $19.5M | $16.4M | $14.6M | $16.8M |
| Total debt | $35.6M | $44.7M | $37.3M | $68.2M | $63.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Guardian Pharmacy Services GRDN | $3.09B | +30% | +5% | 6% | 33.3× | 4.4% |
| CVS Health CVS | $104B | -13% | +7% | 4% | 9.6× | -3.8% |
| BrightSpring Health Services BTSG | $13.6B | +17% | +23% | 4% | 28.8× | 24.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GRDN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +16.6% | +6.7% | highest of 11 |
| 6-month return | +29.8% | +10.3% | highest of 11 |
| Distance from 52-week high | -4.0% | -8.0% | 3rd highest of 11 |
| Revenue growth (TTM) | +4.8% | +6.4% | 4th lowest of 11 |
| Operating margin | 6.3% | 4.8% | 4th highest of 11 |
| Forward P/E | 33.3× | 16.6× | most expensive of 10 |
| Growth the price implies (Req g, 7 yrs) | 4.4% | -9.2% | most demanding of 11 |
| Growth delivered (Del g) | +16.8% | +10.3% | 2nd highest of 11 |
| Hurdle (Req g minus delivered) | -12.4 pp | -20.4 pp | 2nd most demanding of 11 |
| ROIC minus cost of capital | +28.5 pp | +7.6 pp | highest of 11 |
| EV / EBITDA | 26.1× | 7.2× | most expensive of 7 |
| Net debt / EBITDA | -0.7× | -0.3× | 3rd least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guardian Pharmacy Services GRDN | United States | $3.09B | +30% | +5% | 6% | 33.3× | 4.4% | +16.8% |
| Sundrug 9989.T | Japan | $3.07B | +10% | +4% | 6% | 14.9× | -7.3% | +5.8% |
| Sugi 7649.T | Japan | $3.46B | -9% | +9% | 5% | 17.9× | -9.0% | +10.9% |
| DaShenLin Pharmaceutical 603233.SS | China | $3.64B | +10% | +7% | 8% | 15.9× | -9.5% | +13.6% |
| Yifeng Pharmacy Chain 603939.SS | China | $4.84B | +16% | +5% | 10% | 17.2× | -9.3% | +13.2% |
| LBX Pharmacy Chain Joint Stock 603883.SS | China | $1.71B | +13% | +3% | 5% | 16.1× | -10.7% | +9.7% |
| TSURUHA 3391.T | Japan | $7.15B | +17% | +114% | 4% | 23.8× | -1.5% | +9.6% |
| Create SD 3148.T | Japan | $1.32B | +3% | +9% | 5% | n/a | -11.5% | +8.0% |
| MatsukiyoCocokara & 3088.T | Japan | $7.51B | +29% | +6% | 8% | 19.5× | -4.8% | +15.5% |
| Ain 9627.T | Japan | $1.25B | +2% | +42% | 4% | 13.8× | -6.5% | +16.9% |
| Yixintang Pharmaceutical 002727.SZ | China | $1.16B | +4% | -2% | 3% | 16.6× | -16.0% | +6.5% |